BioNTech
NEWS
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.
T follicular helper immune cells help antibody-producing cells create increasingly robust antibodies and also enhance the formation of certain types of immune memory.
Pfizer has reported that an Omicron-specific vaccine will be available in March, should it be necessary. For those and more COVID-19 news, continue reading.
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
As the Omicron strain sweeps the world, researchers rush to determine how effective vaccines are at creating immunity against the variant. For that and more, continue reading.
Pfizer and BioNTech are developing a vaccine for the prevention of shingles while Moderna is in a Phase I study of an mRNA vaccine for the Epstein-Barr Virus.
JOBS
IN THE PRESS